Annovis Bio Enters Material Definitive Agreement

TL;DR

Annovis Bio just signed a big deal, filing an 8-K on Feb 3rd.

AI Summary

Annovis Bio, Inc. announced on February 3, 2025, that it entered into a material definitive agreement. The filing also includes other events and financial statements and exhibits. The company was formerly known as QR Pharma, Inc. and is incorporated in Delaware.

Why It Matters

This filing indicates a significant new agreement for Annovis Bio, which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — Entering into a material definitive agreement can carry inherent risks related to the terms, obligations, and potential outcomes of the agreement.

Key Numbers

• 001-39202 — SEC File Number (Identifies the company's filing history with the SEC.)
• 26-2540421 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• Annovis Bio, Inc. (company) — Registrant
• QR Pharma, Inc. (company) — Former company name
• February 3, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 101 Lindenwood Drive, Suite 225 Malvern, PA 19355 (address) — Principal executive offices

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 ANVS New York Stock Exchange Item 1
• $4.00 — rrant Shares "), at a per unit price of $4.00. for aggregate gross proceeds of $21,00
• $21,000,000 — $4.00. for aggregate gross proceeds of $21,000,000 (the " Offering ") before deducting und
• $5.00 — The Warrants have an exercise price of $5.00 per share, are immediately exercisable

Filing Documents

• tm255497d1_8k.htm (8-K) — 32KB
• tm255497d1_ex1-1.htm (EX-1.1) — 406KB
• tm255497d1_ex4-1.htm (EX-4.1) — 103KB
• tm255497d1_ex4-2.htm (EX-4.2) — 101KB
• tm255497d1_ex5-1.htm (EX-5.1) — 14KB
• tm255497d1_ex99-1.htm (EX-99.1) — 10KB
• tm255497d1_ex99-2.htm (EX-99.2) — 9KB
• tm255497d1_ex99-3.htm (EX-99.3) — 9KB
• tm255497d1_ex5-1img001.jpg (GRAPHIC) — 5KB
• tm255497d1_ex5-1img002.jpg (GRAPHIC) — 2KB
• tm255497d1_ex99-1img01.jpg (GRAPHIC) — 5KB
• tm255497d1_ex99-2img01.jpg (GRAPHIC) — 5KB
• tm255497d1_ex99-3img01.jpg (GRAPHIC) — 5KB
• 0001104659-25-009279.txt ( ) — 1047KB
• anvs-20250203.xsd (EX-101.SCH) — 3KB
• anvs-20250203_lab.xml (EX-101.LAB) — 33KB
• anvs-20250203_pre.xml (EX-101.PRE) — 22KB
• tm255497d1_8k_htm.xml (XML) — 4KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On February 3, 2025, Annovis Bio, Inc. (the " Company ") entered into an Underwriting Agreement (the " Underwriting Agreement ") with ThinkEquity LLC, acting as representative of the underwriters (" ThinkEquity ") with respect to an underwritten public offering of 5,250,000 units of the Company, each unit consisting of one share of its common stock, par value $0.0001 per share (the " Common Stock ") and one warrant to purchase one share of the Company Stock (the " Warrants ") to purchase an aggregate of 5,250,000 shares of Common Stock (the " Warrant Shares "), at a per unit price of $4.00. for aggregate gross proceeds of $21,000,000 (the " Offering ") before deducting underwriting discounts and fees and other estimated offering expenses. The Warrants have an exercise price of $5.00 per share, are immediately exercisable and expire five years from the date of issuance. The shares of Common Stock and Warrants were issued separately. Collectively, the shares of Common Stock, the Warrants and the Warrant Shares are referred to as the " Securities ." In connection with the issuance of the Warrants, the Company entered into a Warrant Agency Agreement, dated February 4, 2025 with Equiniti Trust Company, LLC, as warrant agent (the " Warrant Agency Agreement "). The Securities offered and sold in the Offering were issued pursuant to the Company's shelf Registration Statement on Form S-3, as amended (File No. 333-276814) filed with the Securities and Exchange Commission (the " SEC ") on February 1, 2024, which was declared effective on February 12, 2024, the related prospectus contained therein, and the final prospectus supplement relating to the Offering filed with the SEC on February 4, 2025. The Company intends to use the net proceeds from the Offering, for the continued clinical development of our lead compound Buntanetap in a Phase 3 study for Alzheimer's disease, and for working capital and general corporate pur

01. Other Events

Item 8.01. Other Events On January 31, 2025, the Company issued a press release announcing that the Company had commenced the Offering. On February 3, 2025, the Company issued a press release announcing the pricing of the Offering. On February 4, 2025, the Company issued a press release announcing the closing of the Offering. Copies of the press releases are attached as Exhibits 99.1, 99.2 and Exhibit 99.3, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 1.1 Underwriting Agreement, dated February 3, 2025, by and between Annovis Bio., Inc. and ThinkEquity LLC 4.1 Form of Warrant 4.2 Warrant Agency Agreement 5.1 Opinion of Loeb & Loeb LLP 23.1 Consent of Loeb & Loeb LLP (contained in Exhibit 5.1). 99.1 Press Release Dated January 31, 2025 99.2 Press Release Dated February 3, 2025 99.3 Press Release Dated February 4, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANNOVIS BIO, INC. Dated: February 4, 2025 By: /s/ Maria Maccecchini Name: Maria Maccecchini Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR